Avance Clinical Announces Asia Pacific and Mainland China Expansion Ahead of BIO International Conve
Global CRO expands its operational footprint into Singapore and Malaysia, strengthens China presence, and grows India operations - creating a powerhouse in the Asia Pacific region
ADELAIDE, Australia, June 19, 2026 (GLOBE NEWSWIRE) -- Avance Clinical, the Australian-headquartered global Contract Research Organization (CRO) for biotechs, today announced a significant expansion of its Asia Pacific and China operations, reinforcing its position as the leading CRO partner for international biotech companies seeking access to the region’s diverse patient populations, scientific infrastructure, and accelerated clinical trial timelines.
The expansion extends Avance Clinical’s established Asian footprint - which includes South Korea and Taiwan - to now encompass Singapore and Malaysia, where the company is actively building dedicated clinical operations teams. Simultaneously, Avance Clinical has expanded into mainland China, with commercial operations based in Shanghai and Beijing to serve the country’s rapidly growing biotech innovation hubs. In India, where Avance Clinical has maintained a business presence and biometrics hub, clinical operations are also being scaled to meet increasing demand.
“This expansion reflects the growing strategic importance of Asia Pacific and China to our biotech clients around the world,” said Mark Harvill, Chief Executive Officer of Avance Clinical. “US and international biotechs are increasingly recognising APAC as a high-value region for clinical development - whether for patient access, trial diversity, or speed to key milestones. With boots on the ground across South Korea, Taiwan, Singapore, Malaysia, India, and now mainland China, we can offer an integrated, seamless delivery model that few CROs can match.”
The moves position Avance Clinical to serve as a single accountable partner for multi-country Asian trials, with the regulatory expertise, site relationships, and operational infrastructure to deliver high-quality data that meets global standards.
Jessica Han, Director, Asian Operations, who leads Avance Clinical’s regional strategy from the company’s Seoul, South Korea office, brings over 18 years of clinical research experience across global and regional CROs. “APAC is a collection of highly sophisticated biotech ecosystems, each with its own regulatory frameworks, patient populations, and clinical infrastructure,” said Han. “Our expansion into Singapore and Malaysia opens access to clinical trial clusters that complement our existing strength in Korea and Taiwan, while our China presence means we can now engage directly with the world’s fastest-growing biotech market. For US biotechs this creates unprecedented flexibility in how they design and execute their global development programs.”
Avance Clinical will highlight its expanded APAC and China capabilities at the 2026 BIO International Convention in San Diego, June 22–25, where the company will be exhibiting at Booth #5352. Senior representatives including members of the Asia Operations leadership team will be available throughout the event to discuss multi-regional trial strategies, patient enrolment in APAC, and how Avance Clinical’s GlobalReady delivery model can accelerate development timelines for companies at every stage from First-in-Human through to late-phase pivotal trials.
Biotechs attending BIO International 2026 are encouraged to book a meeting with the Avance Clinical team in advance at www.avancecro.com/book-a-meeting, indicating ‘BIO 2026’ in the notes field.
About Avance Clinical
Avance Clinical is a full-service, Australian-headquartered global Contract Research Organization, servicing international biotechs across North America, Europe, Asia Pacific and China. Specialising in early-phase and First-in-Human studies across more than 250 indications, as well as Oncology, Renal/Cardiometabolic, and Central Nervous System trials, Avance Clinical has partnered with more than 710 emerging biotech companies to accelerate their programs to critical development milestones. Avance Clinical is the 2026 Frost & Sullivan Global Company of the Year in the Biotech CRO industry. To learn more, visit www.avancecro.com.
Find out more:
- Discover Avance Clinical’s GlobalReady model for multi-phase global clinical trials
- Book a meeting with our team at BIO International 2026 in San Diego
- Request a proposal
Media Contact
media@avancecro.com
- 【河北日报】刊发|成安县以工业AI智造引领特色产业集群迭代升级
- 中国农业:绿色发展的引擎与未来希望
- 从“人巡”到“智巡”:中能拾贝水电巡点检管理解决方案,以数智之力重构智慧运维全流程
- 瑞派明星专科:重塑筋骨,守护生命的每一份支撑
- 济南宠物托运公司,提供全程上门接送托运宠物
- 暖冬里的公益人 罗丽
- 七腾机器人亮相重庆2024首台重大技术装备新品发布及成果展
- C.K. McWhorter Slams Nelson Peltz For Attempting To Ruin Disney's Luxury Essence and Visionary
- New Report: Average Annual Natural Catastrophe Losses for the Insurance Industry Reaches New High of
- 著名书画家陈忠洲院长再次当选北京市侨联第十六届常务委员
- PUMA在洛杉矶开设PUMA NITRO™ Lab,将NITRO™科技引入足球领域
- ChinaBio® 2026同期会议 | 4月同来自全球的ADC与CGT产业领袖聚首上海,共绘创新与合作蓝图
- 迈巴赫投资有限公司与InfinityEX(无限交易中心)续签五年战略合作协议
- 全球首创抗癌新药爱谱沙®登陆京东健康 微芯生物深化创新可及通路
- 特德制辊包胶件:工业自动化腾飞的隐形翅膀
- 不将”旧”生活开启,和京东家居卫浴洁具品类日一起爆改卫浴空间!
- 移远通信《5G RedCap技术发展及应用白皮书》重磅发布
- 伍关宗:“牛王”的乡村振兴传奇(《会长传奇》专访之二)
- 硕日新能SRNE Solar 荣获 TÜV NORD 目击实验室认可资质!
- 翁虹联合国教科文演讲:做自己,取悦自己,绽放女性魅力
- 2024“蓉漂杯”绿色低碳产业链主企业命题揭榜赛顺利举行!
- 黄芦英:医者仁心照人间,安居之盼待回响
- 柯尼卡美能达全新推出 AccurioPro Dashboard Essential
- Bitget Wraps Up Anti-Scam Month with Over 65% of Participants Successfully Identifying Crypto Fraud
- 三季度营收净利双升,老板电器如何跑通厨电“硬件+软件”正向循环
- 五大亮点!2024非物质文化遗产(广州)博览会即将开幕!
- Taku联合TopOn发布《2025H1全球应用广告变现报告》
- 香港维尔利健康科技集团受邀参加2025年阿拉伯健康展览与会议,展现全球医疗科技创新实力
- Visa《成长型企业营运资本指数》报告显示了策略规划者和灵活推动者在塑造流动性管理未来上日益重要的作用
- 商业航天黄金期,低轨卫星最具商业价值






